A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

Primary Open Angle GlaucomaOcular Hypertension

Interventions

DRUG

TFC-003

1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.

DRUG

COSOPT ophthalmic solution

1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.

Trial Locations (1)

Kukje Pharm, Seongnam-si